Table 2. What to do to detect and manage Candida auris.

What to do	How
Keep a high index of suspicion	Consider C. auris in patients who: received health care in countries (or US states) where C. auris is prevalent, as tracked by the CDC (4) have a clinical syndrome consistent with candidiasis and fail to respond to empiric antifungal therapy and from whom an atypical or unidentified yeast is isolated
Assess for C. auris specifically	Consult with a microbiologist and/or infectious disease specialist Refer suspicious or confirmed isolates to relevant provincial laboratory for further testing or for referral to the National Microbiology Laboratory
Manage C. auris with a robust clinical infection control and public health response	Notify the institutional infection prevention and control team Notify local public health officials, who will notify their provincial/territorial counterparts (who will notify the Public Health Agency of Canada) Place patient in single room with contact precautions in addition to routine practices In case of symptomatic disease, begin treatment, preferably with guidance from an infectious disease specialist (treatment of asymptomatic colonization is not recommended) Order daily and terminal cleaning of the patient’s environment with sporicidal disinfectant Enable local public health officials to initiate contact tracing and screening to assess for C. auris transmission Order composite swab of axilla and groin when indicated for patient screening

Abbreviations: C. auris, Candida auris; CDC, Centers for Disease Control and Prevention; US, United States